within Pharmacolibrary.Drugs.ATC.N;

model N02CC06
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 0.0006333333333333333,
    adminDuration  = 600,
    adminMass      = 40 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.138,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.006416666666666667,
    Tlag           = 19.8,            
    Vdp             = 0.093,
    k12             = 24,
    k21             = 24
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N02CC06</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Eletriptan is a selective serotonin (5-HT1B/1D) receptor agonist of the triptan class used for the acute treatment of migraine with or without aura in adults. It is approved in many countries for this indication and is not indicated for migraine prophylaxis.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers following single oral administration.</p><h4>References</h4><ol><li><p>Shah, AK, et al., &amp; Morganroth, J (2002). The pharmacokinetics and safety of single escalating oral doses of eletriptan. <i>Journal of clinical pharmacology</i> 42(5) 520–527. DOI:<a href=\"https://doi.org/10.1177/00912700222011571\">10.1177/00912700222011571</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12017346/\">https://pubmed.ncbi.nlm.nih.gov/12017346</a></p></li><li><p>Gawel, MJ, &amp; Grujich, NN (2001). Eletriptan. <i>Expert opinion on investigational drugs</i> 10(10) 1869–1874. DOI:<a href=\"https://doi.org/10.1517/13543784.10.10.1869\">10.1517/13543784.10.10.1869</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11772292/\">https://pubmed.ncbi.nlm.nih.gov/11772292</a></p></li><li><p>Shah, AK, et al., &amp; Apseloff, G (2001). Pharmacokinetics and safety of oral eletriptan during different phases of the menstrual cycle in healthy volunteers. <i>Journal of clinical pharmacology</i> 41(12) 1339–1344. DOI:<a href=\"https://doi.org/10.1177/00912700122012922\">10.1177/00912700122012922</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11762561/\">https://pubmed.ncbi.nlm.nih.gov/11762561</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N02CC06;
